TR201910409T4 - Sitrülin barındıran adjuvan bileşimi. - Google Patents

Sitrülin barındıran adjuvan bileşimi. Download PDF

Info

Publication number
TR201910409T4
TR201910409T4 TR2019/10409T TR201910409T TR201910409T4 TR 201910409 T4 TR201910409 T4 TR 201910409T4 TR 2019/10409 T TR2019/10409 T TR 2019/10409T TR 201910409 T TR201910409 T TR 201910409T TR 201910409 T4 TR201910409 T4 TR 201910409T4
Authority
TR
Turkey
Prior art keywords
adjuvant composition
composition
adjuvant
composition containing
containing citrulline
Prior art date
Application number
TR2019/10409T
Other languages
English (en)
Inventor
Nozaki Chikateru
Kaminaka Kazuyoshi
Matsuda Junichi
Original Assignee
Km Biologics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Km Biologics Co Ltd filed Critical Km Biologics Co Ltd
Publication of TR201910409T4 publication Critical patent/TR201910409T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Alüm gibi geleneksel adjuvana kıyasla güvenlik ve uygunluk bakımından mükemmel olan yeni bir adjuvan bileşimi sağlanmaktadır. Canlı vücutta bulunan suda çözünü madde olan sitrülinleri ve/veya bunun bir tuzunu içeren bir adjuvan bileşimi; söz konusu adjuvan bileşimi ve bir antijeni içeren bir aşı bileşimi; söz konusu adjuvan bileşiminin ve söz konusu aşı bileşiminin hazırlanmasına yönelik bir proses; ve söz konusu adjuvan bileşimi ve söz konusu aşı bileşiminin uygulanmasına yönelik bir yöntem sağlanmaktadır.
TR2019/10409T 2011-03-11 2012-03-09 Sitrülin barındıran adjuvan bileşimi. TR201910409T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011053658 2011-03-11

Publications (1)

Publication Number Publication Date
TR201910409T4 true TR201910409T4 (tr) 2019-08-21

Family

ID=46830703

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10409T TR201910409T4 (tr) 2011-03-11 2012-03-09 Sitrülin barındıran adjuvan bileşimi.

Country Status (8)

Country Link
US (2) US9381242B2 (tr)
EP (1) EP2684572B1 (tr)
JP (1) JP5914458B2 (tr)
KR (1) KR101847848B1 (tr)
CN (1) CN103561764B (tr)
ES (1) ES2731636T3 (tr)
TR (1) TR201910409T4 (tr)
WO (1) WO2012124631A1 (tr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106232577B (zh) 2014-04-25 2019-02-22 味之素株式会社 免疫刺激剂
JP2018188434A (ja) 2017-04-28 2018-11-29 味の素株式会社 免疫賦活剤
CA3121613A1 (en) * 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725545A (en) * 1971-02-03 1973-04-03 R Maes Enhancement of antibody production by nucleic acid-polycation complexes
JPS5375387A (en) 1976-12-13 1978-07-04 Kyowa Hakko Kogyo Co Ltd Preparation of l-citrulline
JPH0755155B2 (ja) 1986-09-10 1995-06-14 協和醗酵工業株式会社 アミノ酸の製造法
US20040062773A1 (en) * 1993-04-22 2004-04-01 Emisphere Technologies Inc. Compositions for the delivery of antigens
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
WO1997049430A1 (en) * 1996-06-26 1997-12-31 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
JP3843298B2 (ja) 2001-02-05 2006-11-08 国立大学法人 奈良先端科学技術大学院大学 シトルリンを含有する活性酸素消去剤
PT1909830E (pt) * 2005-08-02 2011-11-24 Novartis Vaccines & Diagnostic Redução de interferência entre adjuvantes contendo óleo e antigénios contendo tensioactivos
WO2009053535A2 (en) * 2007-10-26 2009-04-30 Glykos Finland Oy Peptide vaccine for influenza virus
EP3011961B1 (en) * 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
JP5349297B2 (ja) 2007-04-20 2013-11-20 一般財団法人化学及血清療法研究所 ペプチド免疫応答増強方法
CN102215836B (zh) * 2008-09-19 2015-07-08 雀巢产品技术援助有限公司 预防或减轻在抗癌治疗期间的骨髓瘫痪或中性白细胞减少症的营养支持
BRPI1005670A8 (pt) * 2009-01-05 2017-12-26 Epitogenesis Inc composições adjuvantes e processos de uso.
AU2010282169A1 (en) * 2009-08-10 2012-03-08 Immunotech Developments Inc. Vaccine having a peptide adjuvant for eliciting a specific immune response to treat viral infection and other conditions
CN102612559B (zh) 2009-08-28 2015-06-10 一般财团法人化学及血清疗法研究所 源自流感m2的修饰的肽疫苗
EP2545071A2 (en) * 2010-03-09 2013-01-16 Maksyutov, Amir Polyepitope constructs and methods for their preparation and use

Also Published As

Publication number Publication date
JP5914458B2 (ja) 2016-05-11
EP2684572A1 (en) 2014-01-15
US20170239348A1 (en) 2017-08-24
CN103561764B (zh) 2015-09-16
WO2012124631A1 (ja) 2012-09-20
US10556005B2 (en) 2020-02-11
JPWO2012124631A1 (ja) 2014-07-24
US20140065179A1 (en) 2014-03-06
CN103561764A (zh) 2014-02-05
US9381242B2 (en) 2016-07-05
EP2684572A4 (en) 2014-09-10
EP2684572B1 (en) 2019-05-22
KR20140012115A (ko) 2014-01-29
ES2731636T3 (es) 2019-11-18
KR101847848B1 (ko) 2018-04-12

Similar Documents

Publication Publication Date Title
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
EA201600305A1 (ru) Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
MX2015000962A (es) COMPLEJO CRISTALINO DE 1-CIANO-2-(4-CICLOPROPIL-BENCIL)-4-(ß-D-GLU COPIRANOS-1-IL)-BENCENO, METODOS PARA SU PREPARACION Y SU USO PARA PREPARAR MEDICAMENTOS.
BR112013003722A2 (pt) produtos para cuidado e métodos de uso e fabricação dos mesmos
ME01199B (me) Nove kompozicije adjuvanta
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
PH12015502535A1 (en) Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
EA201400237A1 (ru) Фолатные конъюгаты альбуминсвязывающих частиц
MX2013012219A (es) Método de administración de vacunas.
NZ606988A (en) Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии
AR082943A1 (es) Formula nutricional predigerida
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201291437A1 (ru) Концентрация вакцинных антигенов без лиофилизации
EA201401117A1 (ru) Композиции, содержащие пробиотики и комплекс пчелиной пыльцы/глины, способ их приготовления и их применение в питании и терапии
MX347911B (es) Vacuna contra virus de diarrea viral de bovinos.